CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

37 Episodes

Reverse

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

2024-04-0512:52

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

2024-03-2915:39

Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.

Juliana M. Kling, MD, MPH - Improving Inclusive Care: Enhancing HPV Vaccine Uptake Among LGBTQ+ Individuals

2024-02-2815:12

Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.

$John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies$

John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

2024-02-1414:30

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

2024-01-2614:11

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.

Nicola A. Hanania, MD, MS - Enough: Targeting Eosinophilic Pathways With Biologics in Chronic Obstructive Pulmonary Disease

2024-01-1215:26

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Michael Wechsler, MD - On the Case to Improve Outcomes in Uncontrolled Asthma: Best Practices to Enhance Clinical Care

2023-12-2916:50

Please visit answersincme.com/NQF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses current guideline-supported best practices in the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids (OCS) in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Jennifer Hill, MD - Breathing New Air Into Improved Outcomes: Strategies to Optimize Care in Patients With Uncontrolled Asthma

2023-12-0515:22

Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Shawn Kwatra, MD - Itching for Relief: Exploring the Role of Novel Biologics in Prurigo Nodularis

2023-10-0616:57

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.

$Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies$

Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

2023-09-1916:50

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Bradley Chipps, MD - Calling the Shots for Pediatric Asthma Control: Integrating Biologics Into the Treatment Plan to Enhance Outcomes

2023-08-1713:29

Please visit answersincme.com/UPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in allergy and respiratory disease discuss patient-centered strategies to improve treatment of children with asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Tina Q. Tan, MD - Easing the RSV Burden in Infants: Looking Ahead to New Prevention Strategies

2023-06-2713:51

Please visit answersincme.com/YXX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics discusses respiratory syncytial virus (RSV) vaccines for infants. Upon completion of this activity, participants should be better able to: Recognize the rationale for considering respiratory syncytial virus (RSV) vaccines for infants; Describe the clinical profiles of emerging long-acting monoclonal antibodies and maternal vaccines for preventing RSV in infants; and Outline strategies for optimal integration of emerging agents, including overcoming barriers to vaccination, for improving patient outcomes.

Gary W. Falk, MD, MS / Ikuo Hirano, MD - Enhancing Outcomes in Adults and Children With Eosinophilic Esophagitis by Targeting Type 2 Inflammation

2023-06-0812:57

Please visit answersincme.com/HQX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of eosinophilic esophagitis (EoE) discuss biologic therapies targeting type 2 inflammation. Upon completion of this activity, participants should be better able to: Identify the role of type 2 inflammation in EoE in the context of treatment implications; and Describe evidence-based strategies to integrate biologics targeting type 2 inflammation into clinical practice for the management of EoE.

Russell D. Cohen, MD, FACG, AGAF - Changing the Course of Ulcerative Colitis: Addressing Unmet Needs Through Effective Disease Severity Assessments and New Therapeutic Strategies

2023-05-3013:45

Please visit answersincme.com/EXY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses the disease severity assessment and treatment of patients with moderately to severely active ulcerative colitis (UC).Upon completion of this activity, participants should be better able to: Identify appropriate strategies to effectively assess disease severity in ulcerative colitis; Describe the rationale for Janus kinase (JAK) inhibitors in targeting the disease pathophysiology in patients with ulcerative colitis; and Outline strategies to individualize the treatment selection for patients with ulcerative colitis.

Tobias Welte, MD - Lowering the Risk of Respiratory Syncytial Virus in Older Adults: Late-Stage Emerging Vaccines

2023-04-1214:16

Please visit answersincme.com/CTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infections and vaccination discusses the rationale for respiratory syncytial virus (RSV) vaccination in older adults and how late-stage emerging vaccines can lower their risk of RSV infection. Upon completion of this activity, participants should be better able to: Recognize the burden of disease associated with RSV in older adults; Describe the clinical rationale for vaccines to prevent RSV in older adults; and Evaluate the latest clinical data for late-stage investigational RSV vaccines in older adults.

Murat Akova, MD / Jeffrey V. Lazarus, PhD, MIH, MA - Region-Specific, Patient-Centered Strategies for Optimizing Uptake of mRNA-Based COVID-19 Vaccination

2023-04-1014:44

Please visit answersincme.com/DMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease discuss the clinical impact of mRNA-based COVID-19 vaccines. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available mRNA-based COVID-19 vaccines; Evaluate the clinical impact of available mRNA-based COVID-19 vaccines; and Apply region-specific, patient-centered strategies to optimize uptake of mRNA-based COVID-19 vaccination.

Christine E. Jones, BMBS, PhD - Preventing Congenital Cytomegalovirus Through Behavioral and Emerging Vaccination Strategies

2023-03-2713:42

Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.

Bruce E. Strober, MD, PhD - Patient Conversations in Plaque Psoriasis: Discussing Novel TYK2 Inhibitors for the Treatment of Patients Who Are Candidates for Systemic Therapy

2023-03-1613:56

Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.

Brian S. Kim, MD - Scratching the Itch: Biologic Breakthroughs in Prurigo Nodularis

2023-03-1613:09

Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for patients with PN; Describe the clinical profiles of approved and emerging biologic therapies for the treatment of PN; and Outline approaches to optimally integrate biologic therapies into treatment plans for PN.

Marc E. Rothenberg, MD, PhD - Closing In on Improved Quality of Life for Patients With Eosinophilic Esophagitis by Targeting Type 2 Inflammation

2023-01-0913:41

Please visit answersincme.com/WBE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses how new and emerging therapeutic options targeting type 2 inflammation can improve quality of life for patients with eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for targeting type 2 inflammatory factors to treat EoE; and Outline individual approaches to optimize therapeutic regimens for patients with EoE.

#box-pro-ellipsis-171422137189123{-webkit-line-clamp:2;}CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases